Medical Oncology Management

Provider Orientation for Blue Cross and Blue Shield of Minnesota



©2020 eviCore healthcare. All Rights Reserved. This presentation contains CONFIDENTIAL and PROPRIETARY information.





Empowering the Improvement of Care

Medical Benefits Management (MBM)

Addressing the complexity of the healthcare system



10 Comprehensive solutions



Evidence-based clinical guidelines



5k⁺ employees, including **1k+ clinicians**



Advanced, innovative, and intelligent technology





Program Overview

©eviCore healthcare. All Rights Reserved. This presentation contains CONFIDENTIAL and PROPRIETARY information.

Blue Cross and Blue Shield Prior Authorization Services

Prior authorization applies to the following services:

- Outpatient Treatment, including Diagnostic
- Infusion and Injectable Chemotherapy
- Supportive Medications given with Chemotherapy under the Medical Benefits
 - Supportive drugs, under the medical benefit, require a separate authorization from the primary chemotherapy regimens. This will be made clear via the clinical pathway questions.

Prior authorization does **NOT** apply to services performed in/for:

- Emergency Rooms including 24
 Hour Observation Services
- Inpatient Stays
- Clinical Trials
- Drugs dispensed via the Pharmacy Benefits



Providers should verify member eligibility and benefits on the secured BCBSMN Availity provider login at <u>www.Availity.com</u>.

Utilization Management – the Prior Authorization Process



Information Needed

Having the following information available will speed up your submission process:

- Patient's member ID and date of birth
- NPI numbers for the referring and rendering providers
- Patient's clinical presentation
- Diagnosis Codes
- Type and duration of treatments performed to date for the diagnosis
- Disease-Specific Clinical Information:
 - ✓ Diagnosis at onset
- Comorbidities

- ✓ Stage of disease
- ✓ Clinical presentation
- ✓ Histopathology

- Patient risk factors
- ✓ Performance status
- ✓ Genetic alterations
- ✓ Line of treatment



Medical Oncology Solution Defines a Complete Episode of Care

eviCore Medical Oncology Guideline Management



Treatment options may be modified to align with formulary

Medical Oncology Solution

Included in the Prior Authorization Regimen:

- Infused and self-administered drugs in the primary treatment of cancer that are part of the Medical Benefit
- Supportive agents included with the approved treatment regimen of cancer-related symptoms
- All medications used that are not associated with the direct treatment of cancer or cancer-related symptoms are <u>outside</u> the scope of this program

Important Details

- > There are <u>no</u> partial approvals.
- > The Authorization is <u>not</u> for a specific dose or administration schedule.
 - However, billing in excess of the appropriate # of units or frequency of administration based on **MUE/NCCN** guidelines for a drug may result in claims denial.
- Supportive drugs, under the medical benefit, will be issued as a separate authorization.
- > Please call eviCore at 844-224-0494 if a change in treatment plan occurs.



Insufficient Clinical – Additional Documentation Needed

Additional Documentation to Support Medical Necessity

If all required pieces of documentation are not received, or are insufficient for eviCore to reach a determination, the following will occur:

A Hold Letter will be faxed to the Requesting Provider asking for specific additional documentation

To ensure that a determination is completed within the designated timeframe, please read the Hold letter carefully. The Provider must submit the additional information to eviCore

Important: Requested information must be received within the timeframe as specified in the Hold Letter. eviCore will review the additional documentation and reach a determination

Determination will be completed once the information is received, or after the timeframe outlined in the Hold letter expires.

Note: For urgent requests, to avoid adverse determinations, it is important to include all clinical information needed to support the request at the time of submission. Determinations on urgent requests are made within 72 hours, and are based solely on the information provided when the case is submitted.

Prior Authorization Decisions

- All requests and corresponding notification are <u>typically</u> processed within 2 business days after receipt of all necessary clinical information. However, depending on the circumstance, eviCore may take the required length of time pursuant to CMS/Medicare or MN state statute to make a determination.
- Authorization date spans <u>vary</u> (typically 8-14 months depending on treatment type).
- Authorization letters will be mailed to the member and copied to the ordering and rendering providers via fax or email. When initiating a case on the web portal, you can receive enotifications and/or print authorization summaries on demand right from the portal.
- Denial letters will be mailed to the member and copied to the ordering and rendering providers via fax or email. The communications will include denial rationale and information on post decision options.



Special Circumstances

Retrospective (Retro) Authorization Requests

 Retrospective reviews are <u>not</u> accepted for **Medical Oncology** requests. Claims may be denied if treatment begins prior to obtaining an authorization.

Urgent Prior Authorization Requests

- Urgent Cases will be reviewed within 24 to 72 hours of the request, and will require all clinical information to be uploaded in order for the case to be processed as urgent.
 - It is imperative that all clinical information is included for eviCore to review. If eviCore is not able to obtain all required documentation, we will have to make a decision based solely on the information provided and could result in an adverse determination.
- Medically urgent requests are defined as conditions that are a risk to the patient's life, health, ability to regain maximum function, or the patient is having severe pain that required a medically urgent procedure.

Clinical Consultations

- eviCore will request a Clinical Consultation on any regimens that do not meet NCCN guidelines prior to issuing a determination.
- If further clinical discussion is needed, we welcome requests for clinical determination discussions from referring physicians. For commercial members, additional information provided during the consultation is sufficient to satisfy the medical necessity criteria for approval.



Pre-Decision Options

I've received a request for additional clinical information. What's next?

Submission of Additional Clinical Information

- You can submit additional clinical information to eviCore for consideration per the instructions received in the Hold letter.
- Additional clinical information must be submitted to eviCore in advance of the due date referenced in the Hold letter.
- For Medicare cases only, eviCore will notify providers telephonically and in writing before a denial decision is issued.

Pre-Decision Clinical Consultation

- Providers can choose to request a Pre-Decision Clinical Consultation instead of submitting additional clinical information.
- The Pre-Decision Clinical Consultation must occur prior to the due date referenced in the Hold letter.
- If additional information was submitted, we proceed with our determination and are not obligated to hold the case for a Pre-Decision Clinical Consultation, even if the due date has not yet lapsed.

Post-Decision Options

Reconsiderations:

- For **commercial members only**, additional clinical information can be provided without the need for a formal appeal.
- Must be requested within **14 calendar days** from the date of determination
 - Can be requested in writing or verbally via clinical consultation (P2P). It is possible to approve a case based on a P2P.
- If an appeal has already been filed, a reconsideration is <u>not</u> allowed
- For Medicare members, reconsiderations are not allowed

Appeals:

- eviCore will process first level appeals
- Requests for appeals must be submitted to eviCore using the process outlined on the denial notification
- The request and all clinical information provided will be reviewed by a physician other than the one who made the initial determination.
- A written notice of the appeal decision will be mailed to the member and faxed to the provider



Provider Portal Overview

©eviCore healthcare. All Rights Reserved. This presentation contains CONFIDENTIAL and PROPRIETARY information.

Benefits of using Availity

Did you know that most providers are already saving time submitting prior authorization requests online? The provider portal allows you to go from request to approval faster. Following are some benefits & features:

- Saves time: Quicker process than phone authorization requests
- Available 24/7: You can access the portal any time and any day
- Save your progress: If you need to step away, you can save your progress and resume later
- Upload additional clinical information: No need to fax in supporting clinical documentation, it can be uploaded on the portal to support a new request or when additional information is requested
- View and print determination information: Check case status in real-time
- Dashboard/worklist: View all recently submitted cases

Methods to Submit Prior Authorization Requests

Availity (preferred)

Availity is the quickest, most efficient way to request prior authorization and check authorization status, and it's available 24/7

Prior Auth call center: 844-224-0494

7:00 a.m. to 7:00 p.m. Central Time Monday - Friday



Check Member eligibility through Availity

New Request	Watch a quick demo	
•Payer 😧	Patient Information	
BCBSMN		
Provider Information	To Date	
Select a Provider 0	Patient Search Option 0	Add Multiple Patients
Search for a Provider	Patient ID, Date of Birth	
NPI 😧	• Patient ID 😧	
Tax ID 👔	* Date of Birth	
Payer Assigned Provider ID 🛛 🕢	Group Number	
Service Information	Patient Relationship to Subscriber 🥑	
As of Date 😧	Self	Ŧ
02/01/2022	Submit another patient	
* Benefit / Service Type 💡		
Health Benefit Plan Coverage 🗱	Sub	mit

To determine member eligibility, start by logging into Availity and enter the information in the fields demonstrated in the screen shots shown here.

Initiating a Case Using the Availity Portal

When submitting a case through Availity.com, if the request will be reviewed by eviCore, you will see the Single Sign-On screen, and will be re-directed to the eviCore portal.

Home > BlueCross BlueShield of Minnesota > Single Sign-On

Single Sign-On

This type of authorization request is administered by eviCore for Blue Cross Blue Shield of Minnesota. To complete your authorization request, you'll need to accept the disclaimer and answer a few more questions.

You are about to be re-directed to a third-party site away from Availity's secure site, which may require a separate log-in. Availity provides the link to this site for your convenience and reference only. Availity cannot control such sites, does not necessarily endorse and is not responsible for their content, products, or services. You will remain logged in to Availity.

Cancel





Important to know...

When using Availity for submitting prior authorizations, you can save your request and finish later if needed



- Available on every clinical pathway screen
- You can resume a saved request through the Availity Dashboard
- You will have <u>48 hours</u> to complete the case, or the case will expire and you'll have to start over

Our Medical Oncology Solution outlines a Complete Episode of Care

- Selection of a recommended treatment regimen will result in immediate approval of all drugs in the requested regimen that require PA with an authorization time span sufficient to complete the entire treatment.
- No further action is needed unless the treatment needs to be changed due to disease progression or other clinical factors.
- Custom treatment plan requests will be reviewed by an eviCore medical oncologist to determine if the request is clinically appropriate.

Provider Portal Overview

Submitting Online Prior Authorization Requests

©eviCore healthcare. All Rights Reserved. This presentation contains CONFIDENTIAL and PROPRIETARY information.



Clinical Certifi	ication			
Select the practione Filter Last Name or NPI:	r or group for wh	FILTER CLEAR FILTER	practitioner, group, or lab for whom you wish to build a case is i	not listed, (
Selected Physician:		Provider		
	SELECT	the second second second		
	SELECT		The Office user will select	
	SELECT		the treating physician from	
	SELECT		their pre-populated affiliated	
	SELECT		physician list.	
Cancel Back Print Contin	ue			
Click here for help or t	echnical support			

5

Clinical Certification	
To process an urgent case on the web you will be re clinical upload feature at the end of the case build	equired to upload relevant clinical information using the online process. Click here for more information!
You selected	
Please select the health plan for which you would like plan at the number found on the member's identifica National is necessary.	e to build a case. If the health plan is not shown, please contact the ation card to determine if case submission through CareCore
PLAN-X	Take note of any important messages and confirm the provider address
Cancel Back Print Continue	
Click here for help or technical support	

Clinical Cer	tification		
Provider's Name Who to Contact	Dave	[?]	
Fax Phone] [?]] [?] Cont	act information is confirmed or
Ext. Cell Phone		enter comr	ed to ensure smooth nunication of the
Email	dspangler@evicore.com] deter addit	mination or to request ional information as needed.
Cancel Back Print C	ontinue		
Click here for help	or technical support		

New Patient Registration	Current Patients
Member ID (no spaces or dashes) Date of Birth (MM/DD/YYYY)	Filter by Physician (type to filter by patient name)
First Name (optional)	New patients are registered current patients are selected from the drop down list. If a
Unable to Unable to Date of Birth: 3/20/1971 Name: City, State:	and eligibility is verified, a confirmation screen will appear. Click "Yes" to continue.

Clinical Certification PO BOX 970 Female PLAN-X ID Female					The Patient all future re Including a services the and dates, information process.	t History Scr equests or da record of pr rough eviCor and clinical s provided th	een becomes the hub for ata relating to this patient. evious requests for re, authorization numbers summaries based on the rough the request
			Re	views	·		
Date	Physician	Case #	Cancer Type	Treatment	Status		
3/04/2019			Colorectal	5-Fluorouracil (5FU; Adrucil), Brentuximab Vedotin (Adcetris)	Pending	VIEW HISTORY	
8/02/2018			Colorectal	Oxaliplatin (Eloxatin)	Approved	VIEW HISTORY	
2/13/2017		Multiple Myeloma Cyclophosphamide (Cytoxan; Endoxan- Asta)		Cyclophosphamide - in (Cytoxan; Endoxan-	ij Approved	VIEW HISTORY	Click to view clinical

Attention! Patient ID : Time: 3/4/2019 2:02 P Patient Name: What is the anticipated start date of treatment? SUBMIT	 Enter: Start Date of Treatment Type of Therapy Select CHEMOTHERAPY for Chemo or Chemo + Supportive drugs Select SUPPORTIVE THERAPIES for Supportive drugs only
Clinical Certification	
This procedure will be performed on 4/1/2019. CHANGE	
Medical Oncology Pathways	
Select type of therapy	
▼ Deplt and your	▼
Primary Chem, CHEMOTHERAPY SUPPORTIVE THERAPIES	parate requests.

Select a Procedure by CPT Code[?] or Description[?]					
CHEMO •	CHEMOTHERAPY		•		
Don't see you Primary Cher	ur procedure code or t notherap y and Suppor	type of service tive drugs mu	Select ICD10	by entering code or c	lescription
Diagnosis Select a Prim	ary Diagnosis Code (Lo	ookup by Code or	Description)		
Diag	nosis Code	Descriptio	n		
SELECT C18.2	Malignant	neoplasm of ascend	ling colon		
SELECT C18.4	Malignant	Malignant neoplasm of transverse colon			
SELECT C18.6	Malignant	Malignant neoplasm of descending colon			
SELECT C18.7	Malignant	Malignant neoplasm of sigmoid colon			
SELECT C18.8	Malignant	neoplasm of overla	oping sites of colon		
SELECT C18.9	Malignant	neoplasm of colon,	unspecified		

Clinical Certification

Confirm your service selection.

Procedure Date:	4/1/2019	and make correct
Medical Oncology Pathways:	CHEMO	
Description:	CHEMOTHERAPY	
Primary Diagnosis Code:	C18.9	
Primary Diagnosis:	Malignant neoplasi	m of colon, unspecified
Secondary Diagnosis Code:		
Secondary Diagnosis:		
Change Procedure or Primary Diagnos	is	
Change Secondary Diagnosis		
Cancel Back Print Continue		

Click here for help or technical support

Confirm the information entered or use the 'change' links to go back and make corrections as needed.

Distinct rendering site or facility can be entered if needed. Multiple lookup options are available.

NPI:		Zip	Code: 441	45	Site Name:	
TIN:		Cit	y: clev	reland		Exact match
						 Starts with
				Name		Address
	SELECT			Name	WESTLAKE, OH 44145	Address
	SELECT	_		Name	WESTLAKE, OH 44145	Address

ri₹			
Selected Site:	An email can be submitted for communication if desired.		
Site Email (optional)			
Cancel Back Print Continue			
Click here for help or technical support			

Specific Site Search

Clinical Certification

You are about to enter the clinical information collection phase of the autr the clinical portion are displayed.

After answering the clinical question(s) on each screen you will need to hit of the clinical questions you must hit "Submit" before exiting the system. Ye

The demographic portion of the case is complete. Reminders on how to complete the clinical portion are displayed. Click 'Continue to proceed to the clinical review.

information that you have provided. Hit "Submit" and your request for a prior authorization will be submitted for review.

Your answers to previous questions will be displayed on the lower portion of the screen. If you made an error during the clinical data collection process you can click on the question. The system will ask that you answer the question again and subsequent questions. You can use the "Finish Later" button, for Standard/Routines cases only, to save information and return to this case at a later time. This will save all case information recorded up to but not including the current screen.

Failure to formally submit your request by clicking the "Submit" button after the attestation will cause the request for a prior authorization to expire with no additional correspondence.

Cancel Back Print Continue

Click here for help or technical support

Clinical Certification						
🕕 Indicate the Cancer Type:						
Colon/Rectal Cancer 🔹						
Anal Bladder						
Bone						
Brain and Spinal Cord Tumors (CNS Tumors)						
Breast Consor Rick Reduction						
Cervical Cancer						
Colon/Rectal Cancer						
Endometrial Cancer						
Ewing's Sarcoma						
Gallbladder Cancer						
Gastric/Esophageal Cancer						
Head and Neck Cancers						
Hepatic (Liver) Cancer						
Kidney Cancer						
Leukemia - Acute Lymphoblastic Leukemia (ALL)						
Leukemia - Acute Myeloid Leukemia (AML)						
Leukemia - Chronic Lymphocytic Leukemia (CLL)						
Leukemia - Chronic Myelogenous Leukemia (CML) 🔻						
You can save a certification						
request to finish later.						

The Clinical pathways begin with selection of the cancer type. This will dictate the questions that will be asked in the following screens. All cancer types covered by NCCN are available and an "Other" option is included for rare cancers not addressed by NCCN.

Cancel Print

Exclusions are confirmed.

Clinical Certification

1) Please select any/all services that the patient is participating in that includes injectable and oral chemotherapy drugs:

Clinical Trials
Non-cancer uses of the drug (not related to treatment of chemo or chemo side effects)

Inpatient Chemo

🔲 Stem Cell Transplant

SUBMIT

1	Clinical Certifica	tion		
Clinical Certifi Initial AJCC (Pathol O I IIA IIA IIB IIC IIIA IIIB IIIC IV Unknown SUBMIT		tion stage) Stage at DIAGNOSIS: lect treatment type: herapy for a patient who is coadjuuvant chemotherapy High Risk Pathologic Fe High Risk Pathologic Fe• <12 nodes exam	(Adjuvant) locally unresectable or medically inoperable for clinical T4b disease prior to colectomy atures aned ated histology lar or perineural invasion on ation nate or positive margins	The office user will be asked a series of questions necessary to generate the recommended treatment list for the patient being treated. A typical traversal will have between 5 and 12 questions based on the complexity of the cancer. The system will dynamically filter to only the
		Most recent entry for	this patient: None	minimum number of questions needed to complete the review.
		Ves O No	 KRAS/NRAS Result: Wild Type (no mutation) Mutation Positive Testing Not Completed/Unknown Status 	Almost all answers are in drop down or click selection to allow for quick entry.
			SUBMIT	

Previously Appro	oved Treatments (listed in chronological order): None ent Option:	All NCCN recommended treatments are displayed, as well as the option to Build a Custom Treatment Plan.
	Regimen	
•	Fluorouracil (Simplified Biweekly Infusional) + Leucovorin	
•	mFOLFOX6 (Fluorouracil + Leucovorin + Oxaliplatin)	
•	Capecitabine	
•	CapeOx (Capecitabine + Oxaliplatin)	
•	Fluorouracil + Leucovorin (Roswell Park Regimen)	
•	Build a Custom Treatment Plan (May Require Additional Clinical Review)	
SUBMIT		

Clinical Certification

Select the chemotherapy drug(s) for the treatment regimen from the Drug List below.

- If you are able to select the treatment option using the Drug List, provide administration s from a drop down list and the
- If a chemotherapy drug is not on this list, and it is a newly approved chemotherapy drug t have the drug added to the treatment regimen.

Custom Treatment plans can be submitted for any case where the provider does not want to use a recommended regimen. Drugs are selected from a drop down list and the user has the opportunity to attach or enter supporting information for the request.

🕕 Drug List:

	Add all	2 items selected	Remove all
5FU (5-Fluorouracil)	+ ^	5-Fluorouracil (Adrucil, 5)	U) –
Abemaciclib - oral (Verzenio)	+	Capecitabine - oral (Xelod	a) _
Abiraterone Acetate - Zytiga - oral (Zytiga)	+		Clinical Certification
Abiraterone Acetate -Yonsa - oral (Yonsa)	+		
Abraxane (Paclitaxel (albumin-bound))	+		The treatment regimen is not recommended by NCON. If you think a mistake has been made during the case regimens will not be immediately approved and require Clinical Review. Supporting clinical information should b
Acalabrutinib - oral (Calquence)	+		Documentation to support your proposed treatment should be submitted in the following manner: • Free text in box below
Actemra (Tocilizumab)	+		Attach documentation to case Fax documentation to case Fax documentation to 866-889-8061. Include patient name and the case reference number. If you need additional time, click "Save and Exit" and return by clicking "RESUME".
Actimmune (Interferon, gamma-1b)	+		Submit all relevant information about this case within 2 business days.
Adcetris (Brentuximab Vedotin)	+		Enter supporting Clinical Information in the field below:
Ado-Trastuzumab Emtansine (Kadcyla)	+		A
Adriamycin (Doxorubicin HCL)	+		
Adrucil (5-Fluorouracil)	+		
Afatinib - oral (Gilotrif)	+ -		You may attach up to 5 PDF or Word documents no larger than 1 MB each.
			Attach a PDF or Word document: click "Browse" to select the document from your desktop or other netw Browse

Your case has be	en Approve	ed.		
Provider Name:			Contact:	dave
Provider Address:	100	VE L	Phone Number: Fax Number:	
Patient Name: Insurance Carrier:	PLAN-X		Patient Id:	1000
Site Name: Site Address:			Site ID:	-
Diagnosis/ICD-9 Code:	153.9		Description:	MALIGNANT NEO COLON NOS
Date of Service: HCPCS Code(s):	2/2/2015 J9263		Drug(s):	OXALIPLATIN (ELOXATIN)
Authorization Number:				
Review Date:	03/05/2019			
Start Date: Expiration Date: Status:	03/10/2019 11/10/2019 Your case ba	s been	Approved.	

Selection of a recommended regimen will result in immediate approval of all drugs in the requested regimen with an authorization time span sufficient to complete the entire treatment. No further action is needed unless the treatment needs to be changed due to disease progression or other clinical factors.

Short cut for adding supportives

Print Go to Patient History Request Supportives

Provider Experience – Case Submission - Supportives

Clinical Certification

Confirm your service selection.

Procedure Date:	5/5/2016
Medical Oncology Pathways	:SPORT
Description:	SUPPORTIVE THERAPIES
Diagnosis Code:	C18.9
Diagnosis:	Malignant neoplasm of colon, unspecified
Change Procedure or Diagnosis	

Cancel Back Print Continue

Click here for help or technical support

If "Request Supportives" is selected, a new case is started and the user is dropped on this screen to complete a supportive drug request. The start date, drug classification, and ICD10 are prepopulated to match the Chemotherapy case. Click Continue to proceed to the clinical portion of the request

Provider Experience – Case Submission - Supportives

Clinical Certifica	tion
Onfirm Cancer type	
Colon/Rectal Cancer	
SUBMIT	Clinical Certification
	 Indicate the requested supportive agent: Darbepoetin alfa (Aranesp) ONCE EVERY 2 WEEKS Darbepoetin alfa (Aranesp) ONCE EVERY 3 WEEKS Darbepoetin alfa (Aranesp) WEEKLY FIXED DOSE Darbepoetin alfa (Aranesp) WEEKLY WEIGHT BASED DOSE Denosumab (Prolia) Denosumab (Xgeva) MONTHLY Denosumab (Xgeva) MONTHLY and DAY 8, 15 Epoetin alfa (Epogen, Procit) 3 TIMES PER WEEK Epoetin alfa (Epogen, Procit) ONCE EVERY 2 WEEKS Epoetin alfa (Epogen, Procit) ONCE EVERY 2 WEEKS Epoetin alfa (Epogen, Procit) ONCE EVERY 3 WEEKS Epoetin alfa (Epogen, Procit) WEEKLY Filgrastim (Neupogen) 300 mcg single use syringe/vial Filgrastim (Neupogen) 480 mcg single use syringe/vial Granisetron (Sustol) Octreotide (Sandostatin LAR Depot) Octreotide (Sandostatin) Pegfilgrastim (Neulasta) Telotristat ethyl - oral (Xermelo) Build a Custom Treatment Plan (May Require Additional Clinical Review)

User will be asked to indicate the drug needed and may be asked for additional clinical information to support that request. If multiple supportive drugs are needed a separate request must be entered for each drug.

Your case has	been cent for M	ledical Revie		
Four case has been sent for medical Review.				
Provider Name:		Contact:	dave	
Provider Address:		Phone Number:		
		Fax Number:		
Patient Name: Insurance Carrier:	PLAN-X	Patient Id:		
Site Name:		Site ID:	EC4953 The sum	nmary screen
Site Address:			details o	of the request.
Diagnosis/ICD- 9 Code:	153.9	Description:	MALIGNANT NEO COLON	
Date of Service: HCPCS Code(s):	03/05/2019 39190, 39042	Drug(s):	5-FLUOROURACIL (5FU; ADRUCIL), BRENTUXIMAB VEDOTIN (ADCETRIS)	
Case Number: Review Date:	03/05/2019			
Expiration Date:	N/A			
Status:	Your case has been			
Print Go to Patient Histor	~			

Provider Resources

©eviCore healthcare. All Rights Reserved. This presentation contains CONFIDENTIAL and PROPRIETARY information.

Dedicated Call Center

Prior Authorization Call Center – 844-224-0494

Our call centers are open Monday through Friday, from 7 a.m. to 7 p.m. (central time).

Providers can contact our call center to perform the following:

- Request Prior Authorization
- Check Status of existing authorization requests
- Discuss questions regarding authorizations and case decisions
- Change facility or CPT Code(s) on an existing case
- Request to speak to a clinical reviewer
- Schedule a clinical consultation with an eviCore Medical Director



Online Resources at eviCore.com



Web-Based Services and Online Resources

- You can access important tools, health plan-specific contact information, and resources at <u>www.evicore.com</u>
- Select the Resources to view Clinical Guidelines, Online Forms, and more.
- Provider's Hub section includes many resources
- Provider forums and portal training are offered regularly by eviCore. You can find a session on <u>www.eviCore.WebEx.com</u>, select WebEx Training, and search upcoming for a "eviCore Portal Training" or "Provider Resource Review Forum"
- If you need assistance with the eviCore portal, our dedicated Web Support team can assist providers in navigating the portal and addressing any webrelated issues during the online submission process. To speak with a Web Specialist, call (800) 646-0418 (Option #2) or email portal.support@evicore.com

Client & Provider Operations Team

Client and Provider Services

Dedicated team to address provider-related requests and concerns including:

- Notification letter issues
- eviCore Healthcare standard processes & procedures
- General (non-formal/legal) complaints including provider complaints
- Issues experienced during case creation
- Eligibility issues member, rendering facility, and/or ordering physician
- Claim issues and appeal questions
- · Peer to Peer issues and escalations

How to Contact our Client and Provider Services team

Email: <u>ClientServices@evicore.com</u> (preferred)

Phone: 1 (800) 646 - 0418 (option 4)

For prompt service, please have all pertinent information available. When emailing, make sure to include "BCBSMN" in the subject line with a description of the issue. Also, please share member/provider/case details when applicable.



Provider Resource Website

Provider Resource Pages

eviCore's Provider Experience team maintains provider resource pages that contain client- and solution-specific educational materials to assist providers and their staff on a daily basis. The provider resource page will include, but is not limited to, the following educational materials:

- Frequently Asked Questions
- Quick Reference Guides
- Provider Training
- CPT code list

To access these helpful resources, please visit

https://www.evicore.com/healthplan/bluecrossmn

Blue Cross and Blue Shield of Minnesota resources via Availity: https://apps.availity.com/availity/web/public.elegant.login



Thank You!



©eviCore healthcare. All Rights Reserved. This presentation contains CONFIDENTIAL and PROPRIETARY information.